BridgeMD
Tests treatment safety and results for Self-Injurious Behavior
Official title Efficacy of Triple-daily 15mA tACS on Adolescent NSSI
ClinicalTrials.gov ID: NCT06919432
What this study is testing
- What it's testing
- In order to assess the clinical efficacy of triple-daily 15mA-tACS stimulation by comparing the effects of active and sham tACS interventions on driving improvements in adolescent Nonsuicidal Self-Injury(NSSI), participants will be randomly assigned to either the active or sham tACS group. This trial consists of a 2-week intensified intervention phase (40 sessions), followed by a 4-week observation period.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 21
You may be able to join if
- Diagnosis of NSSI based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria section 3 diagnostic criteria.
- Five or more NSSI episodes in the past year and at least one NSSI episode in the past month.
- Age between 12 and 21 years.
- Informed consent from parents or legal guardians.
- Informed consent from participants aged 15 years and above.
You likely can't join if
- Current or history of organic brain disorders or neurological disorders.
- Elevated or imminent suicidal risk, as assessed by clinicians during routine screening.
- Previous or current exposure to electroconvulsive therapy (ECT), modified ECT, TMS, transcranial direct current stimulation (tDCS), tACS, or other...
- Presence of cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain.
- Previous or current use of psychotropic medication.
- Pregnancy or lactation.
See the full eligibility criteria
- Diagnosis of NSSI based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria section 3 diagnostic criteria.
- Five or more NSSI episodes in the past year and at least one NSSI episode in the past month.
- Age between 12 and 21 years.
- Informed consent from parents or legal guardians.
- Informed consent from participants aged 15 years and above.
- Current or history of organic brain disorders or neurological disorders.
- Elevated or imminent suicidal risk, as assessed by clinicians during routine screening.
- Previous or current exposure to electroconvulsive therapy (ECT), modified ECT, TMS, transcranial direct current stimulation (tDCS), tACS, or other neurostimulation treatments.
- Presence of cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain.
- Previous or current use of psychotropic medication.
- Pregnancy or lactation.
- Participation in another concurrent clinical trial.
- Refusal to provide informed consent to participate in the trial.
- Other circumstances deemed unsuitable for participation by researchers.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 21 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.